Riot Blockchain, Inc. (NASDAQ:RIOT) stock has moved 421.28% to a low 52-week low and showed -69.21% change to a 52-week high. Going toward the technical facts and figures, its current distance is -33.34% from 20-Day Simple Moving Average and standing away from 50-Day Simple Moving Average with -31.44% while traded 69.08% from 200-Day Simple Moving Average.
Riot Blockchain, Inc. (NASDAQ:RIOT) today declared that it has selected Christopher Ensey as its Chief Operating Officer. Mr. Ensey comes to Riot from Dunbar Security Solutions, where he served as Dunbar’s Chief Operating Officer managing over 150 security professionals across physical and digital operations while capturing over 100 mid to large enterprise clients.
“Chris brings a strong wealth of corporate experience in cyber security and a passion for blockchain technology to Riot,” commented John O’Rourke, Chairman and CEO of the Company. “He has long-standing enterprise relationships from his experience at IBM and Dunbar, and a technical depth in blockchain technology from his active involvement in the space over the past five years.”
Analysts have a mean recommendation of 3.00 on this stock. The company holds 10.10M outstanding shares and 6.52M shares are floating in market. The stock has a beta value of 2.59. It sustained ROA (TTM) at -87.50%. The stock’s short float is around of 36.63% and short ratio is 0.37. Insider’s ownership held at 2.50% and Institutional owners keep 4.80% ownership in the company.
Bioptix, Inc., through its subsidiary, BiOptix Diagnostics, Inc., develops enhanced surface plasmon resonance technology platform for the detection of molecular interactions. The company also focuses on animal healthcare and owns important intellectual property rights related to veterinary products. In addition, it has granted a license relating to single chain reproductive hormone technology for use in no-human mammals, which is under active development by the licensee bovine rFSH. The company was formerly known as Venaxis, Inc. and changed its name to Bioptix, Inc. in November 2016. Bioptix, Inc. was founded in 2000 and is based in Castle Rock, Colorado.